- Home
- SYRE vs PEB Comparison
SYRE vs PEB Comparison
Compare SYRE & PEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- PEB
- Stock Information
- Founded
- SYRE 2013
- PEB 2009
- Country
- SYRE United States
- PEB United States
- Employees
- SYRE N/A
- PEB N/A
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- PEB Real Estate Investment Trusts
- Sector
- SYRE Health Care
- PEB Real Estate
- Exchange
- SYRE Nasdaq
- PEB Nasdaq
- Market Cap
- SYRE 1.1B
- PEB 1.2B
- IPO Year
- SYRE 2016
- PEB 2009
- Fundamental
- Price
- SYRE $16.23
- PEB $10.70
- Analyst Decision
- SYRE Strong Buy
- PEB Hold
- Analyst Count
- SYRE 6
- PEB 8
- Target Price
- SYRE $57.60
- PEB $12.29
- AVG Volume (30 Days)
- SYRE 681.2K
- PEB 3.2M
- Earning Date
- SYRE 11-06-2025
- PEB 11-05-2025
- Dividend Yield
- SYRE N/A
- PEB 0.38%
- EPS Growth
- SYRE N/A
- PEB N/A
- EPS
- SYRE N/A
- PEB N/A
- Revenue
- SYRE N/A
- PEB $1,469,933,000.00
- Revenue This Year
- SYRE N/A
- PEB $2.18
- Revenue Next Year
- SYRE N/A
- PEB $2.96
- P/E Ratio
- SYRE N/A
- PEB N/A
- Revenue Growth
- SYRE N/A
- PEB 2.00
- 52 Week Low
- SYRE $10.91
- PEB $7.42
- 52 Week High
- SYRE $40.26
- PEB $15.12
- Technical
- Relative Strength Index (RSI)
- SYRE 52.04
- PEB 39.75
- Support Level
- SYRE $15.87
- PEB $11.33
- Resistance Level
- SYRE $17.18
- PEB $11.71
- Average True Range (ATR)
- SYRE 0.88
- PEB 0.32
- MACD
- SYRE 0.08
- PEB -0.15
- Stochastic Oscillator
- SYRE 70.65
- PEB 3.21
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About PEB Pebblebrook Hotel Trust of Beneficial Interest
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.